Biotech Xenova aims at Cantab
The British Biotech group Xenova has announced plans to buy rival Cantab Pharmaceuticals for 62 million pounds. Xenova drops of 10% on investor concerns that the merger does not result in a good interaction between the two research centers.
Related posts
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.